Lupin Appoints Brian Savage as Chief Legal Officer

Nature of change: Appointment of Mr. Brian Savage as Senior Management Personnel, designated as President, Chief Legal Officer
Name and details: Mr. Brian Savage (no DIN provided in disclosure)
Effective date: October 22, 2026
Term: Full-time employment
Profile and qualifications: Brings extensive legal leadership experience in the global pharmaceutical industry with deep expertise in legal and regulatory matters, litigation management and strategic business partnering. Previously worked with Teva Pharmaceuticals, where he held various senior leadership roles, most recently serving as Executive Vice President and Interim Global Chief Legal Officer. Prior to Teva, practiced law at Dechert LLP. Holds a Juris Doctor (J.D.) degree from Yale Law School and a Bachelor of Arts degree from the University of Pennsylvania.
Responsibilities: Will oversee the Company's Global Legal, Compliance and IP functions
Relationship with other directors: Not applicable (as per disclosure)
Previous KMP: Not disclosed in the filing
Governance implications: As Chief Legal Officer, will be responsible for legal, compliance and intellectual property functions globally

No financial or operational approvals mentioned in this disclosure.

No specific strategic or business context provided beyond the appointment announcement.

Regulatory compliance: Disclosure made pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular dated January 30, 2026 (reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026)
Company representative: Amit Kumar Gupta, Company Secretary and Compliance Officer (ACS - 15754) signed the disclosure
Filing date: October 22, 2026